Citius reports LYMPHIR momentum with nine-month revenue and expansion
Aug 14, 2026, 4:35 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The company shows real revenue from LYMPHIR, an expanding payer-supported rollout, and an enlarged commercial team. Positive Phase 1 signals (86% ORR pre-CAR-T; 24% with pembrolizumab) de-risk upside and expand TAM; cash runway improvements reduce near-term liquidity concerns. Historically, small biotech with expanding commercial momentum and favorable data tends to re-rate on a multi-quarter horizon, aided by licensing partnerships or increased institutional adoption.
AI summary
What happened, with direct paths to the underlying reporting
Citius Pharmaceuticals flags LYMPHIR momentum alongside a solid near-term funding base: nine-month LYMPHIR revenue of $7.1 million and a cash balance of $17.0 million as of June 30, 2026. The expanded commercial platform and favorable Phase 1 data at ASCO/ASTCT suggest LYMPHIR could scale beyond CTCL, potentially expanding the addressable market and accelerating physician adoption.
LYMPHIR nine-month revenue reached $7.1M; deployed to 44 institutions.
Expanded LYMPHIR commercial/medical team to 29; nationwide deployment completed.
Phase 1 ASCO/ASTCT data show strong activity; 86% ORR pre-CAR-T; 24% with pembrolizumab.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
